Ibodutant was a candidate drug for

irritable bowel syndrome Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by a group of symptoms that commonly include abdominal pain, abdominal bloating, and changes in the consistency of bowel movements. These symptoms may ...

diarrhea, developed by The

Menarini The Menarini Group is an Italian pharmaceutical company. Its headquarters is in Florence, Tuscany, and it has three divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. It develops pharmacological solutions for cardiovascular ...

Group. , it underwent a multicentre double blind efficacy clinical

study Study or studies may refer to: General * Education **Higher education * Clinical trial * Experiment * Field of study * Observational study * Scientific study * Research * Study skills, abilities and approaches applied to learning Other * Study ...

. Ibodutant selectively blocks the tachykinin receptor NK₂, with blockade practically complete in nano molar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.

See also

References

Further reading